Axsome Therapeutics Acquires CNS Drug Candidate from Takeda

Axsome Therapeutics has significantly expanded its central nervous system (CNS) drug development pipeline through the acquisition of balipodect, a selective phosphodiesterase 10A (PDE10A) inhibitor, from Takeda. This strategic move aims to address unmet needs in treating schizophrenia and Tourette syndrome, potentially offering a novel therapeutic approach for millions affected by these debilitating conditions.

The newly acquired asset, previously known as TAK-063, has demonstrated promising results in early-stage clinical trials. Balipodect has successfully completed a 164-patient proof-of-concept Phase 2 study for schizophrenia and has shown a favorable safety and tolerability profile across more than 360 individuals in total. Axsome plans to initiate Phase 3 trial-enabling activities for the schizophrenia indication within 2026, signaling a rapid progression for the compound.

This acquisition aligns with Axsome Therapeutics' mission to tackle complex neurological and psychiatric disorders. The company, already recognized for its work in major depressive disorder, narcolepsy, and migraine, sees balipodect's unique mechanism of action as a valuable addition. Dr. Herriot Tabuteau, CEO of Axsome, expressed confidence in the compound's potential, stating, “We believe that its new and potentially first-in-class mechanism of action is relevant to multiple neuropsychiatric conditions, and we are well positioned to advance its development initially in schizophrenia and Tourette syndrome.”

The market for schizophrenia treatments is substantial, with approximately 3.7 million individuals in the United States affected by the condition and related psychotic disorders. Schizophrenia is characterized by positive, negative, and cognitive symptoms, often leading to significant functional impairment and reduced life expectancy. Current treatment options, while improving, still leave considerable room for innovation, particularly in addressing the full spectrum of symptoms and improving long-term outcomes. The global market for antipsychotics, a primary treatment for schizophrenia, is projected to reach tens of billions of dollars in the coming years, underscoring the commercial opportunity for novel therapies.

Balipodect's mechanism involves inhibiting PDE10A, an enzyme predominantly found in the striatum. This inhibition is believed to modulate downstream signaling pathways influenced by dopamine, offering a distinct therapeutic target. Notably, preclinical and clinical data suggest balipodect does not elevate glucose or prolactin levels, potentially offering a metabolic advantage over some existing treatments. This selectivity is attributed to the enzyme's specific expression pattern and the drug's activity profile.

Under the terms of the agreement, Axsome Therapeutics secured exclusive worldwide commercial, development, and manufacturing rights to balipodect. While the specifics of the upfront payment and milestone structures were not fully disclosed, Takeda is set to receive additional payments contingent on development, regulatory, and commercial achievements for the initial indications, along with royalties on future global net sales. This deal structure reflects the inherent risks and potential rewards in late-stage pharmaceutical development.